Dyne Therapeutics (DYN) Net Equity Issued and Repurchased (2020 - 2025)
Dyne Therapeutics (DYN) posted quarterly Net Equity Issued and Repurchased of $377.7 million for Q4 2025, up 168.53% quarter-over-quarter from $140.7 million in Q1 2025.
Dyne Therapeutics (DYN) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Dyne Therapeutics (DYN) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $377.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $377.7 million; the TTM figure through Jun 2026 stood at $377.7 million (up 168.53% YoY), while the FY2025 annual figure was $140.7 million, up 43.71% from the prior year.
- Net Equity Issued and Repurchased climbed to $377.7 million in Q4 2025 per DYN's latest filing, from $140.7 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $377.7 million in Q4 2025 and bottomed at -$1000.0 in Q4 2023.
- Historically, Net Equity Issued and Repurchased has averaged $95.5 million across 3 years, with a median of $28.2 million in 2023.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 160.81% in 2024 and fell as far as 0.45% in 2024.
- Dyne Therapeutics' Net Equity Issued and Repurchased stood at -$1000.0 in 2023, then jumped by 2425100.0% to $24.2 million in 2024, then soared by 1457.53% to $377.7 million in 2025.
- Business Quant data shows DYN's Net Equity Issued and Repurchased at $377.7 million in Q4 2025, $140.7 million in Q1 2025, and $24.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 377.70 Mn |
| Dec 31, 2025 | 377.70 Mn |
| Mar 31, 2025 | 140.65 Mn |
| Mar 31, 2025 | 140.65 Mn |
| Jun 30, 2024 | 24.25 Mn |
| Jun 30, 2024 | 24.25 Mn |
| Mar 31, 2024 | 73.62 Mn |
| Mar 31, 2024 | 73.62 Mn |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Jun 30, 2023 | 24.14 Mn |
| Jun 30, 2023 | 24.14 Mn |
| Mar 31, 2023 | 28.23 Mn |
| Mar 31, 2023 | 28.23 Mn |
| Dec 31, 2020 | -134,000.00 |
| Dec 31, 2020 | -134,000.00 |
| Mar 31, 2020 | 1.97 Mn |
| Mar 31, 2020 | 1.97 Mn |